CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism

Ester Coutinho, Leslie Jacobson, Marianne Giørtz Pedersen, Michael Eriksen Benros, Bent Nørgaard-Pedersen, Preben Bo Mortensen, Paul J Harrison, Angela Vincent

ABSTRACT
BACKGROUND, METHODS AND OBJECTIVES: Maternal autoantibodies to neuronal proteins may be one cause of neurodevelopmental disorders. This exploratory study used the Danish archived midgestational sera and their nationwide registers to search for antibodies to the N-methyl-D-aspartate receptor (NMDAR) and contactin-associated protein-like 2 (CASPR2) in maternal sera, and to relate them to subsequent psychiatric diagnoses in the woman or her child.

RESULTS: In a sample of 192 women, there was no association between antibody status and subsequent psychosis in the mothers. However, NMDAR antibodies (n=4) or CASPR2 antibodies (n=1) were identified in 5/11 (45.5%) women whose children were given a diagnosis of mild or unspecified mental retardation or disorders of psychological and motor development (collectively abbreviated as mental retardation and/or disorders of psychological development (MR/DPD)) compared with 9/176 (5.1%) of the remaining mothers (p<0.001). These findings were followed up in a specifically selected cohort, in which CASPR2 antibodies were detected in 7/171 (4.1%) mothers of MR/DPD progeny, compared with only 1/171 (0.6%) control mother (p=0.067). The combined sample showed a significantly higher frequency of CASPR2 antibodies in mothers of MD/DPD children (p=0.01). These autoantibodies were not increased in mothers of children with autistic spectrum disorder.

CONCLUSIONS: These findings complement the known roles of CASPR2 in brain development, and warrant further epidemiological and experimental studies to clarify the role of CASPR2 and possibly other antibodies in neurodevelopmental disorders.

INTRODUCTION
A role for autoantibodies is increasingly apparent for several neuropsychiatric phenotypes, including encephalitis, epilepsy and psychosis. Prominent among the identified neuronal surface targets are the N-methyl-D-aspartate receptor (NMDAR) and contactin-associated protein-like 2 (CASPR2). Meanwhile, transfer of immunoglobulin G (IgG) antibodies from mother to the fetus during pregnancy may be one cause of neurodevelopmental changes in their offspring. However, the identity of specific extracellular targets, the importance of autoantibodies as risk factors and the range of disorders in affected children are undetermined.

NMDAR antibodies have been reported in women with postpartum psychosis, and such women may be at higher risk for children with neurodevelopmental disorders, so we first asked whether neuronal surface antibodies were raised in mothers with subsequent psychosis and whether they were associated with an increased incidence of neurodevelopmental disorders in their children. Based on the results, we then looked at specifically selected samples for CASPR2 and NMDAR antibodies in mothers of children with mild or unspecified mental retardation and/or disorders of psychological development (MR/DPD). For comparison, we also tested 190 samples from mothers of children given a diagnosis of autism and control mothers.

METHODS
Cohorts
The pregnancy screening biobank at the State Serum Institute stores serum samples taken from more than 100 000 women who gave birth in five Danish counties from 1977 to 1997. In Denmark, all residents can be linked to clinical registries and biobanks. We used the nationwide Danish Psychiatric Central Research Register (DPCRR) to identify the following samples in the biobank:

Cohort A: This included first trimester mothers with a first diagnosis of schizophrenia spectrum disorder (International Classification of Diseases (ICD)-8: 295, 297, 298.39, 301.83; ICD-10: F20–F29) at some time after delivery (n=94, cases) and mothers without a history of schizophrenia spectrum disorder (n=93, controls) in the DPCRR. A posthoc analysis looked for a diagnosis of psychiatric or neurodevelopmental diseases (ICD-10 codes F20–F39, F70–F79, F80–F89, F90–F98) in the index child (serum sample collected during that pregnancy) from the DPCRR.

Cohort B: This included gestational week 14–18 mothers of children with mild or unspecified MR/DPD (ICD-10: F70, F79, F80–F83.9, F88–F89.9) (n=171, cases) and mothers whose child had not...
received these diagnoses by the age at diagnosis of the case (n=171, controls) in the DPCRR.

Cohort C: This included gestational week 14–18 mothers of children with an autism spectrum disorder (ASD; ICD-10: F84.0, F84.1, F84.5, F84.8, F84.9) (n=95, cases) and mothers whose child had not received these diagnoses by the age at diagnosis of the case (n=95, controls) in the DPCRR.

Cases and controls from all cohorts were matched on parity and age at delivery (±365 days) and also on gender of offspring in cohorts B and C.

Antibody screening

We screened samples for serum IgG-specific antibodies binding to NMDAR or CASPR2 (all cohorts) and Leucine Rich Glial Inactivated 1 (LGI1), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor) and gamma-aminobutyric acid receptor b (GABABR) antibodies (cohort A only) using live immunofluorescent cell-based assays as performed in the Oxford laboratory for clinical diagnoses.6-10 These assays involve binding of serum IgG-specific antibodies to live human embryonic kidney cells transfected with cDNA encoding the different proteins. This cell-based assay uses a fluorescent-tagged secondary antibody (Alexa Fluor goat anti-human IgG, Invitrogen; A21090) that reacts with the human IgG heavy chains and the light chains of all classes of immunoglobulin. To confirm positivity and avoid detection of IgM antibodies (which are not transferred to the fetus), positive samples were additionally screened using a secondary antibody targeting the Fc region of IgG (goat anti-human Fc IgG; Thermo Scientific 31125) followed by detection with the appropriate fluorescent-tagged tertiary antibody (Alexa Fluor donkey anti-goat IgG, Invitrogen A-11055). All samples were sent fully coded and decoding was done after reporting the results back to the Danish partners. Samples were only considered positive if agreed by two observers and also confirmed by the anti-IgG specific assay (two samples were insufficient for confirmation). This additional confirmatory step was done retrospectively for cohort A on coded samples. Seropositivity was scored visually on a non-linear scale from 0 to 4.6-10

Statistics

In this exploratory study, Fisher’s exact tests were used to compare differences as described in the text; p<0.05 (two-tailed) was considered significant.

Ethics

The study was approved by the Danish Data Protection Agency and the Research Ethics Committee. All samples were coded, and experiments and analyses conducted blind to case status.

RESULTS

Cohort A: mothers with a diagnosis of psychosis after delivery and matched controls

Of all the pregnant women, 11 (5.8%) had NMDAR antibodies (7/94 in mothers with subsequent psychosis vs 4/93 in control mothers (p=0.54)) and 3 (2%) had CASPR2 antibodies (1/94 and 2/93, respectively), with no relationship of antibodies with later psychosis in the mothers (p=0.78; see table 1). All samples were negative for LGI1, AMPAR or GABABR antibodies.

However, when the records of the children were examined, a total of 28/187 (15%); both psychosis mothers and controls) had a neuropsychiatric disorder diagnosis (see table 1). NMDAR or CASPR2 antibodies were present in 5/28 (18%) of their mothers compared with only 9/159 (6%) of the remaining mothers without such diagnoses in their offspring (p=0.04). Strikingly, 5/11 (46%) mothers whose children received diagnoses in the category of MR/DPD had NMDAR antibodies (n=4; 36%) or CASPR2 antibodies (n=1, 9%), compared with 9/176 (5%; 7 NMDAR antibodies, 2 CASPR2 antibodies) mothers of children without these diagnoses (p=0.0004; see table 2). The association between maternal NMDAR antibody and neurodevelopmental disease was significant (p=0.0018), but the results for CASPR2 antibodies (1/11 vs 2/176) did not reach significance (p=0.17). None of the children had received a diagnosis in the autism spectrum.

Cohort B: mothers with MR/DPD and matched controls

Given the unpredicted finding of an association of maternal autoantibodies with MR/DPD, we then sought to corroborate this observation by studying a cohort of 171 mothers with children with MR/DPD and 171 control mothers. As expected11 for these diagnoses, there were more males than females (112 M, 59 F) in affected children and gender-matched controls.

NMDAR antibodies were not different between mothers with or without children with MR/DPD (10/171 (6%) vs 9/171 (5%)). By contrast, there was a trend towards more frequent CASPR2 antibodies (7/171; 4%) in the mothers of the children with MR/DPD compared with 1/171 (1%) of the control mothers (p=0.067). The children of these seven mothers did not show any gender predominance (4 M, 3 F). Two of the children had a diagnosis of mental retardation with or without impairment of behaviour, while the other five children had mixed specific developmental disorders, specific developmental disorders of motor function, speech articulation or reading disorders, or unspecified disorders of psychological development. Further information was restricted by Danish data protection regulations.

Figure 1A shows an example of a maternal serum binding to CASPR2-transfected cells, comparing with a control serum. Combining the data from cohorts A and B, CASPR2 antibodies were identified in 8/182 (4%) mothers with children with MR/DPD and only 3/347 (1%) in mothers of children without these diagnoses (p=0.01; figure 1B). NMDAR antibodies were

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Results of cohort A according to neuropsychiatric diagnoses of the mother and offspring</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mothers with subsequent psychosis and individually matched control mothers</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Mothers with subsequent psychosis and individually matched control mothers</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Mother</strong></td>
<td><strong>CBA-positive</strong></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Psychosis</td>
<td>NMDAR/CASPR2</td>
</tr>
<tr>
<td>No psychosis</td>
<td>93</td>
</tr>
<tr>
<td>Offspring</td>
<td></td>
</tr>
<tr>
<td><strong>Developmental disorder</strong></td>
<td></td>
</tr>
<tr>
<td>MR/DPD</td>
<td>28</td>
</tr>
<tr>
<td>Schizophrenia</td>
<td>11</td>
</tr>
<tr>
<td>Hyperkinetic disorders</td>
<td>7</td>
</tr>
<tr>
<td><strong>Multiple diagnoses (not including MR/DPD)</strong></td>
<td></td>
</tr>
<tr>
<td>No neurodevelopmental disorder</td>
<td>159</td>
</tr>
</tbody>
</table>

CASP2, contactin-associated protein-like 2; MR/DPD, mental retardation and/or disorders of psychological development; NMDAR, N-methyl-D-aspartate receptor. CBA = cell-based assay.
Keywords

Table 2  Antibodies in maternal sera and their associations with MR/DPD in the offspring

<table>
<thead>
<tr>
<th>Neurropsychiatric/developmental diagnosis of children</th>
<th>MR/DPD Positive/Total (%)</th>
<th>No MR/DPD Positive/Total (%)</th>
<th>Fisher’s p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cohort A:</strong> mothers with subsequent psychosis and individually matched control mothers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Either antibody</td>
<td>5/11 (45.5)</td>
<td>9/176 (5.1)</td>
<td>0.0004</td>
</tr>
<tr>
<td>CASPR2-Ab</td>
<td>1/11 (9.1)</td>
<td>2/176 (1.1)</td>
<td>0.17</td>
</tr>
<tr>
<td>NMDAR-Ab</td>
<td>4/11 (36.0)</td>
<td>7/176 (4.0)</td>
<td>0.0018</td>
</tr>
<tr>
<td><strong>Cohort B:</strong> mothers of children with mental retardation and other disorders of psychological development and individually matched control mothers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASPR2-Ab</td>
<td>7/171 (4.1)</td>
<td>1/171 (0.6)</td>
<td>0.067</td>
</tr>
<tr>
<td>NMDAR-Ab</td>
<td>10/171 (5.8)</td>
<td>9/171 (5.3)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td><strong>Combined analysis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASPR2-Ab</td>
<td>8/182 (4.4)</td>
<td>3/347 (0.9)</td>
<td>0.01</td>
</tr>
<tr>
<td>NMDAR-Ab</td>
<td>14/182 (7.7)</td>
<td>16/347 (4.6)</td>
<td>0.17</td>
</tr>
</tbody>
</table>

MR/DPD as defined here includes children with a mild or unspecified mental retardation with or without impairment of behaviour, specific developmental disorders of scholastic skills or other disorders of psychological development.

CASPR2, contactin-associated protein-like 2; MR/DPD, mental retardation and/or disorders of psychological development; NMDAR, N-methyl-D-aspartate receptor. Significant p values are in bold.

Present in 14/182 (8%) mothers with children with MR/DPD and in 16/347 (5%) other mothers (p=0.17; table 2).

Cohort C: mothers of children with autism and matched controls

During the later stages of this work, we became aware that others had identified CASPR2 antibodies in mothers of children with autism. However, in a cohort of samples from 95 mothers of children with a diagnosis of ASD, we did not find an excess of CASPR2 antibodies (one female, 1%) compared with the mothers of children without this diagnosis (one male, one female, 2%, p>0.99), and the overall positivity was very similar to that in the non-MR/DPD groups above (ie, around 1%; table 3).

NMDAR antibodies were also not different between mothers with or without children with ASD (2/95 (2%) vs 3/95 (3%), table 3).

DISCUSSION

The aetiology of intellectual disability (MR) or of specific developmental brain disorders is unknown in many cases. There are genetic associations, reflecting multiple alleles of small effect, and rare cases with gene mutations or copy number variants. Maternal immunity is a relatively unexplored area. We linked a gestational serum biobank and patient register to show that maternal antibodies to a specific neuronal antigen, CASPR2, were associated with MR/DPD disorders in the progeny. Our results are the first to identify a specific target for potentially fetopathogenic antibodies in a large human gestational cohort.

Previous published data apply primarily to mothers of children diagnosed with ASD, rather than intellectual disability per se or the neurodevelopmental disorders identified here. Recently, CASPR2 antibodies were reported in 37% of a selected (brain-reactive) subgroup of mothers of autistic children compared with 8%–12% in the control groups; these authors demonstrated in an experimental model that a cloned maternal human CASPR2 antibody, applied during gestation, led to features of autism in male mouse offspring. However, we found no evidence for an increased prevalence of CASPR2 antibodies in the mothers of children with ASD, with only one CASPR2 antibody-positive patient in the autism cohort (n=95).

Nevertheless, our results confirm that CASPR2 is a good candidate for antibody-associated neurodevelopmental disorders.

CASPR2 has an important role during neurodevelopment, being necessary for the correct formation of neural circuits through maturation of dendritic spines and control of dendritic arborisation. Variants of CNTNAP2, the gene encoding CASPR2, have been found in patients with ASD and in other neurodevelopmental disorders, such as psychosis, intellectual disability and speech impairment. Antibodies to CASPR2

Figure 1  (A) Representative photomicrographs of the cell binding of a CASPR2-positive and a CASPR2-negative sample in the live cell-based assay (serum dilution 1:100; score 1.5). Scale bar: 20µm. (B) CASPR2 antibody binding scores (0–4; negative <1) in mothers of children with MR/DPD and control mothers (combined results of cohorts A and B) and in mothers of children with ASD and control mothers (cohort C). CASPR2 antibodies were five times more common in mothers of children given a diagnosis of MR/DPD, but not different between mothers of children with ASD and control mothers. Endpoint dilution antibody titres were generally low to modest, 1:100 (screening dilution) to 1:300, consistent with the scores shown. ASD, autism spectrum disorder; CASPR2, contactin-associated protein-like 2; MR/DPD, mental retardation and/or disorders of psychological development.

Table 3  Antibodies in maternal sera and their associations with autism in the offspring

<table>
<thead>
<tr>
<th>Psychiatric diagnosis of children</th>
<th>ASD Positive/Total (%)</th>
<th>No ASD Positive/Total (%)</th>
<th>Fisher’s p value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cohort C:</strong> mothers of children with ASD and individually matched control mothers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CASPR2-Ab</td>
<td>1/95 (1.1)</td>
<td>2/95 (2.1)</td>
<td>&gt;0.99</td>
</tr>
<tr>
<td>NMDAR-Ab</td>
<td>2/95 (2.1)</td>
<td>3/95 (3.2)</td>
<td>&gt;0.99</td>
</tr>
</tbody>
</table>

ASD, autism spectrum disorder; CASPR2, contactin-associated protein-like 2; NMDAR, N-methyl-D-aspartate receptor.
are present in adult patients with a variety of neurological syndromes. It seems likely that maternal CASPR2 antibodies transferred during pregnancy could impair the function of the protein during fetal brain development. Whether these antibodies are responsible for diagnoses of MR/DPD (or ASD) in the offspring, and the mechanisms involved, will require further careful analyses and animal models. Our data using a similar model system to that mentioned above also demonstrate long-lasting changes in brain histology and behaviour in mice exposed to CASPR2 antibodies in utero (Ester Coutinho and Angela Vincent, under revision).

There are evident limitations and aspects for further study. Although NMDARs are important in intellectual development, and NMDAR antibodies are most frequent in young adult females, and occasionally cause postpartum psychosis, we did not find a reproducible association between gestational NMDAR antibodies and maternal psychosis or MR/DPD in the progeny, although NMDAR antibodies were more frequent overall in both groups. Regarding maternal CASPR2 antibodies, there was only a trend (p=0.067) towards association with a diagnosis of MR/DPD in the offspring, unless we combined the data from both cohorts, which was not our a priori intention. Moreover, the levels of antibodies were often low (see figure 1 legend), unlike the higher titres (>1:500) typically found in patients with autoimmune encephalitis, it can be partly explained by decreased immunity in pregnancy, increased plasma volume and transfer of IgG to the fetus during pregnancy. Unfortunately, at these low levels, confirmatory tests for CASPR2 antibodies, such as immunohistochemistry or binding to live neurons, are not positive in our hands (Ester Coutinho, Angela Vincent unpublished results). Third, the CASPR2 antibodies were also found in four control mothers overall, indicating that there are likely other factors that determine their pathogenicity, such as expression levels of the neonatal Fc receptor, timing of the antibodies in relation to the maximum potential damage to the developing brain or the existence of additional proinflammatory cytokines. Fourth, phenotypic overlap between ASD and MR/DPD can occur, but this was not possible to explore due to data protection.

Despite the limitations, these data should stimulate further research, both epidemiological and experimental, into the role of CASPR2 and other potentially pathogenetic maternal antibodies in disorders of brain development. This study found an association between maternal CASPR2 antibodies and a diagnosis of MR/DPD in the progeny, but it is possible that other antibodies targeting other, yet unknown, neuronal antigens might be present in the maternal sera. The association found in this study, although interesting and potentially relevant, needs further validation in other patient cohorts, and the pathogenic potential of CASPR2 antibodies needs to be established in appropriate animal models, as in the study of Brimberg et al and our own (Ester Coutinho and Angela Vincent, under revision). Only then may we be able to translate these findings into clinical practice, and possibly offer prenatal screening to mothers with multiple affected pregnancies, in line with other antibody-mediated neonatal and neurodevelopmental disorders.

Contributors EC and AV conceptualised the study. EC and AV were responsible for methodology, EC, LI, MGP and MEB conducted the investigation. AV obtained resources. PH, PBM, BN-P and AV supervised the study. EC and AV wrote the manuscript. All authors revised the manuscript.

Funding EC is funded by Programme for Advanced Medical Education, Fundação Calouste Gulbenkian. This work was also supported by the Stanley Medical Research Institute.

Competing interests AV and the University of Oxford hold a patent for LG11 and CASPR2 antibodies, licensed to Euroimmun AG, and receive a proportion of royalties for autoimmune encephalitis diagnostics.

Patient consent Historical cohort under Danish research ethics.

Ethics approval Danish Data Protection Agency and the Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism

Ester Coutinho, Leslie Jacobson, Marianne Giørtz Pedersen, Michael Eriksen Benros, Bent Nørgaard-Pedersen, Preben Bo Mortensen, Paul J Harrison and Angela Vincent

*J Neurol Neurosurg Psychiatry* published online June 1, 2017

Updated information and services can be found at:

[http://jnnp.bmj.com/content/early/2017/06/01/jnnp-2016-315251](http://jnnp.bmj.com/content/early/2017/06/01/jnnp-2016-315251)

**References**

This article cites 17 articles, 3 of which you can access for free at:

[http://jnnp.bmj.com/content/early/2017/06/01/jnnp-2016-315251#BIBL](http://jnnp.bmj.com/content/early/2017/06/01/jnnp-2016-315251#BIBL)

**Open Access**

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**

Articles on similar topics can be found in the following collections

- Open access (241)

**Notes**

To request permissions go to:

[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:

[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:

[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)